Hyperspectral Imaging for Prediction of Preeclampsia
Trial Parameters
Brief Summary
Preeclampsia is a hypertensive pregnancy disorder that can quickly lead to serious, potentially life-threatening outcomes for both the mother and the fetus. Typical features of preeclampsia are by endothelial and microvascular dysfunctionsNotably, such impairments in endothelial function may precede preeclampsia diagnosis and canpersist for years postpartum. In clinical practice, however, no predictive methods have yet been established that specifically reflect endothelial dysfunction in the context of preeclampsia. Hyperspectral imaging represents a new and non-invasive imaging modality that allows contact-free visualization of peripheral microcirculatory dynamics and tissue perfusion. Despite its growing use in other medical fields, this technology has not yet been systematically studied to determine its predictive potential in preeclampsia. The HIPPA project (Systematic Evaluation of Hyperspectral Analysis for Prediction of Preeclampsia) is a prospective observational study to evaluate the applicability of hyperspectral imaging as a new tool for prediction of preeclampsia.
Eligibility Criteria
Inclusion Criteria: * singleton pregnancies * age ≥ 18 years * patient's ability to provide consent * written informed consent * women scheduled for a routine ultrasound scan in first or second trimester Exclusion Criteria: * lack of consent * language barrier * severe fetal chromosomal/genetic/structural anomalies known at study enrollment * smoking in the last two hours before measurement * diagnosis of preeclampsia at study enrollment